🇺🇸 FDA
Pipeline program

Pimavanserina 34 mg placebo cápsulas, Pimavanserin tartrate

IRSP-PSI-2024-171

Phase 2 small_molecule active

Quick answer

Pimavanserina 34 mg placebo cápsulas, Pimavanserin tartrate for Major depressive disorder is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).

Program details

Company
The George Institute
Indication
Major depressive disorder
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials